Pros | - | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Larger AUM within category. | ||
Cons | - | - |
INDMoney rank | - | 2/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 1 Years | 6 Years | ||
Fund Size | 417 Cr | 5508 Cr | ||
Min Investment | SIP ₹1000 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.75% | 1.06% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | Nifty Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 24 | 41 | ||
Top 5 Holdings | Divi's Laboratories Ltd (9.89%) Aster DM Healthcare Ltd Ordinary Shares (9.46%) RPG Life Sciences Ltd (7.87%) Sequent Scientific Ltd (6.8%) Pfizer Ltd (6.49%) | Sun Pharmaceuticals Industries Ltd (12.66%) Dr Reddy's Laboratories Ltd (9.66%) Divi's Laboratories Ltd (9.03%) Cipla Ltd (7.85%) Aurobindo Pharma Ltd (6.34%) | ||
No of Sectors | 5 | 3 | ||
Top 3 Sectors | Health (79.88%) Government (8.23%) Consumer Defensive (7.17%) | Health (94.88%) Basic Materials (3.81%) Financial Services (1.31%) | ||
Equity % | 99.79% | 96.99% | ||
Debt % | - | - | ||
P/E | 34.55 | 30.46 | ||
P/B | 4.74 | 4.13 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 1.17% | 1.49% | ||
3-Month Return | 12.08% | 7.77% | ||
6-Month Return | 1.43% | 0.05% | ||
1-Year Return | 8.52% | 23.69% | ||
3-Year Return | - | 30.57% | ||
5-Year Return | - | 25.42% |
Sharpe | - | 1.3 | ||
Alpha | - | 4.24 | ||
Beta | - | 0.95 | ||
Standard Deviation | - | 15.67 | ||
Information Ratio | - | 1.44 |
Description | Quant Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Sanjeev Sharma,Ankit A. Pande | Dharmesh Kakkad |